Navigation Links
Breast Cancer Therapeutics in Major Developed Markets to 2021 - Growth Driven by Rapid Uptake of Premium Priced Biologics and Rising Incidence
Date:2/4/2016

LONDON, Feb. 4, 2016 /PRNewswire/ -- Summary

Breast cancer, a malignant neoplasm, is the second most common cancer and the most common cancer in women worldwide, accounting for 16% of all female cancers, making the disease exceedingly prevalent. The number of women diagnosed with breast cancer has increased over the past few decades, but the number of deaths has declined due to earlier diagnosis and better treatment options.

Breast cancer treatment has been revolutionized in the past four decades, especially with increasing usage of targeted therapies. The marketed products landscape comprises a wide range of treatment options, including hormonal therapies, chemotherapies, combination therapies, and targeted therapies. Nevertheless, significant unmet need remains for products that can improve overall survival rate, time to disease progression, and overall response.

Scope

The current breast cancer market contains novel products, including Perjeta, a targeted therapy; Kadcyla, a human antibody-drug conjugate; and Halaven, a novel chemotherapeutic agent.
- What are the competitive advantages of the existing novel drugs?
With over 700 active pipeline molecules, most of the investigational drug candidates are being evaluated for the first-line or second-line treatment of advanced-stage breast cancer, featuring new combination therapies, targeted therapies, and promising immunotherapies, as well as chemotherapy drug candidates.
- Which classes of novel drugs are most prominent within the pipeline?
- Is there strong potential for the pipeline to address unmet needs within the breast cancer market?
Analysis of clinical trials since 2006 identified that the failure rates of breast cancer molecules were highest in Phase II (41%), with the overall attrition rate for breast cancer in development being 61%.
- How do failure rates vary by product stage of development, molecule type, and mechanism of action?
- How do other factors, such as average trial duration and trial size influence the costs and risks associated with product development?
Over the 2014–2021 forecast period, the breast cancer therapeutics market in the eight major markets is expected to increase in value at a CAGR of 7.3%, from $10.4 billion to over $17.2 billion.
- Which markets make the most significant contribution to the current market size?
- What are the epidemiology trends in these markets?
- Will new market entrants lead to substantial changes in annual therapy costs?
- How will different treatment usage patterns impact growth in the eight major markets?
Rising breast cancer incidence and new product approvals will lead to significant market growth over the forecast period, despite generic sales erosion resulting from patent expirations.
- Will patent expirations or emerging pipeline molecules threaten the commercial success of existing drugs?
- Which patent expirations will have the most significant impact on the market?

Reasons to buy

This report will enable you to -
- Understand the clinical context of breast cancer by considering symptoms, etiology, pathophysiology, epidemiology, diagnosis, and treatment options.
- Identify the therapeutic strategies, products, and companies that dominate the current marketed products landscape and recognize gaps and areas of unmet need.
- Identify key pipeline trends in molecule type, administration route, mechanism of action, and novelty.
- Consider market opportunities and potential risks by examining trends in breast cancer clinical trial size, duration, and failure rate by stage of development, molecule type, and mechanism of action.
- Recognize the late-stage pipeline molecules that have demonstrated strong therapeutic potential in breast cancer by examining clinical trial data and multi-scenario product forecast projections.
- Compare treatment usage patterns, annual therapy costs, and market growth projections for the US, Canada, the UK, France, Germany, Italy, Spain, and Japan.
- Discover trends in licensing and co-development deals concerning breast cancer products and identify the major strategic consolidations that have shaped the commercial landscape.

Download the full report: https://www.reportbuyer.com/product/3596610/

About Reportbuyer
Reportbuyer is a leading industry intelligence solution that provides all market research reports from top publishers
http://www.reportbuyer.com

For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: query@reportbuyer.com
Tel: +44 208 816 85 48
Website: www.reportbuyer.com


'/>"/>
SOURCE ReportBuyer
Copyright©2016 PR Newswire.
All rights reserved


Related medicine technology :

1. Global Breast Pumps Market Assessment & Forecast: 2015 - 2019
2. Morphotek Announces Collaboration with Mayo Clinic to Apply Its Folate Receptor Alpha Diagnostic Assays in a Phase II Clinical Trial in Triple-Negative Breast Cancer
3. United States Breast Cancer Diagnostic Devices Market to Cross $ 2 billion by 2020: Pharmaion Report
4. When It Comes To Breast Diagnostic Technology, One Size Does Not Fit All
5. Largest Breast Cancer Study of its Kind Suggests Several New Potential Drug Targets and Combinations
6. Breast Biopsy Market by Product, Type & by Guidance system - Forecast to 2020
7. Global Breastfeeding Pump Market 2015-2019 - Battery-Powered Breast Pumps Dominating Market
8. Breast Cancer Therapeutics Market to be Dominated by HER2 Inhibitors - Transparency Market Research
9. Higher Breast Cancer Rates Will Push Treatment Market Beyond $17 Billion by 2021, says GBI Research
10. Automated Breast Ultrasound System (ABUS) Market: Global Industry Analysis and Opportunity Assessment, 2015 - 2025
11. 100th Provider Joins MarginProbe Program to Improve Breast Cancer Surgery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2019)... (PRWEB) , ... September 18, ... ... parent organization to ReachMD, Global Learning Collaborative, and other healthcare-focused subsidiaries, today ... environment, DecisionSimâ„¢, uses real-world cases to challenge healthcare professionals (HCPs) to make ...
(Date:9/18/2019)... ... 2019 , ... The interns of NJ Lenders Corp. recently spent their time ... Foundation (YCS) in Hackensack , where NJ Lenders donated $1,000 worth of school supplies ... them a pizza party and handed out ice cream. , NJ Lenders is a ...
(Date:9/18/2019)... ... ... U.S. Dermatology Partners was a proud sponsor of the 9th Annual ... took place at Lake Ray Hubbard in Rockwall. Over 340 swimmers raised $270,000 and ... helps fund phase 1 clinical trials for cancer research for difficult to treat cancers ...
Breaking Medicine Technology:
(Date:9/17/2019)... ... September 17, 2019 , ... ... Keflezighi and the American Heart Association (AHA)-San Diego Chapter to raise awareness of ... Stroke Walk on Saturday, September 21 in Balboa Park alongside National University System ...
(Date:9/17/2019)... ... 2019 , ... Drs. Charles Felts and Elizabeth Felts Randall ... TN for customized full mouth dental implants with TeethXpress® . TeethXpress treatment ... a permanent tooth replacement solution for patients who struggle with the pain and ...
(Date:9/17/2019)... ... September 17, 2019 , ... Specialty Technical ... updated International Audit Protocol Consortium (IAPC) EHS audit protocol for Japan . ... scope of their EHS regulatory obligations and rapidly collect, share, archive, and export ...
(Date:9/14/2019)... ... September 13, 2019 , ... ... on the detection and treatment of infectious diseases at its annual Congress ... were noninvasive detection of residual HIV infected cell persistence and the development ...
(Date:9/11/2019)... ... ... A September 2 article on CBS News details a new ... to suffer heart attacks, strokes, kidney failure, and heart disease versus a control group ... specialists Dr. Feiz and Associates says the study adds further evidence to an overwhelming ...
Breaking Medicine News(10 mins):